ArticleAntimicrobial agents and chemotherapy2022
Critically Ill Patient with Multidrug-Resistant Acinetobacter baumannii Respiratory Infection Successfully Treated with Intravenous and Nebulized Bacteriophage Therapy.
Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 59 citations in OpenAlex.
- Review
- Approaching the post-antibiotic era: phage therapy current practices and future horizons.mBio · 2026Review
- Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The effects of bacteriophage cocktail treatment on healthy gut microbiota: anMicrobial genomics · 2026Article
- Hospital-adapted inhaled phage therapy for ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae: a comparative pilot study.Critical care (London, England) · 2026Article
- Phage Therapy: Application and Related Problems-A Review.Life (Basel, Switzerland) · 2025Review
- Bacteriophages as an alternative strategy for the treatment of drug resistant bacterial infections: Current approaches and future perspectives.Cell surface (Amsterdam, Netherlands) · 2025Review
- A Century of Bacteriophages: Insights, Applications, and Current Utilization.Antibiotics (Basel, Switzerland) · 2025Review
- Antibiotic-resistant Acinetobacter baumannii can be killed by a combination of bacteriophages and complement.Medical microbiology and immunology · 2025Article
- [Potential of bacteriophage therapy in Germany: evidence and clinical relevance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Review
- The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions.Antibiotics (Basel, Switzerland) · 2025Review
- Antibiotic Use in Livestock Farming: A Driver of Multidrug Resistance?Microorganisms · 2025Review
- Re-Emergence of Bacteriophages and Their Products as Antibacterial Agents: An Overview.International journal of molecular sciences · 2025Review
- The intricacies ofFrontiers in microbiology · 2025Review
- Characterization of phage HZY2308 against Acinetobacter baumannii and identification of phage-resistant bacteria.Virology journal · 2024Article
- Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens.Pathogens (Basel, Switzerland) · 2024Review
- Whole-genome sequencing of two multidrug-resistant acinetobacter baumannii strains isolated from a neonatal intensive care unit in Egypt: a prospective cross-sectional study.BMC microbiology · 2024Article
- Resistance to bacteriophage incurs a cost to virulence in drug-resistantJournal of medical microbiology · 2024Article
- Phage therapy: breathing new tactics into lower respiratory tract infection treatments.European respiratory review : an official journal of the European Respiratory Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hospitalized patients are at risk of developing serious multidrug resistant bacterial infections. This risk is heightened in patients who are on mechanical ventilation, are immunocompromised, and/or have chronic comorbidities. We report the case of a 52-year-old critically ill patient with a multidrug resistant Acinetobacter baumannii (MDR-A) respiratory infection who was successfully treated with antibiotics and intravenous and nebulized bacteriophage therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.